ZYMtronix and Almac collaborate on a National Science Foundation (NSF)-sponsored project

Project will allow both companies to provide efficient immobilised catalysts for the mild and selective oxidation of chemical intermediates and APIs

ZYMtronix and Almac Group are collaborating on a National Science Foundation (NSF)-sponsored project focusing on the stabilisation and immobilisation of metabolic enzymes for bio-oxidation applications.

These enzymes have the potential to be powerful tools to access difficult-to-synthesise drug metabolites and oxidation products. However, they can be relatively unstable under chemical processing conditions and difficult to use in production.

‘Almac is the ideal partner for ZYMtronix to deploy its universal enzyme immobilisation platform to enhance Almac’s mono-oxygenase enzyme collection. The project will allow both companies to provide the industry with efficient immobilised catalysts for the mild and selective oxidation of chemical intermediates and APIs with reduced production costs,’ said Dr Stéphane Corgié, CEO of ZYMtronix.

Professor Tom Moody, Head of Biocatalysis at Almac commented: ‘We look forward to adding ZYMtronix technology to our expanding biocatalysis capabilities. Although mono-oxygenases have great potential for efficient synthesis of otherwise difficult-to-access products, implementation has been limited by slow reaction rates and need for high enzyme loadings. ZYMtronix technology has the potential to overcome these limitations.’

Featured Companies

Almac Group (more information, website)
NSF Health Sciences (more information, website)